Artivion, Inc. (NYSE:AORT) Receives $32.40 Average Price Target from Analysts

Shares of Artivion, Inc. (NYSE:AORT - Get Free Report) have earned a consensus rating of "Buy" from the six analysts that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $32.40.

A number of equities research analysts have commented on AORT shares. Canaccord Genuity Group assumed coverage on Artivion in a report on Tuesday, June 17th. They set a "buy" rating and a $35.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $32.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Citizens Jmp raised Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. Finally, JMP Securities reiterated a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a report on Tuesday, May 6th.

Insider Activity at Artivion

In other Artivion news, Director Anthony B. Semedo sold 2,600 shares of the business's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $28.47, for a total transaction of $74,022.00. Following the completion of the transaction, the director directly owned 33,059 shares of the company's stock, valued at $941,189.73. The trade was a 7.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Marshall S. Stanton sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $29.50, for a total transaction of $442,500.00. Following the completion of the sale, the senior vice president owned 64,200 shares in the company, valued at $1,893,900. The trade was a 18.94% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,954 shares of company stock worth $2,108,525 in the last ninety days. 7.60% of the stock is owned by insiders.

Institutional Trading of Artivion

Several hedge funds have recently added to or reduced their stakes in AORT. Charles Schwab Investment Management Inc. increased its holdings in shares of Artivion by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 358,192 shares of the company's stock valued at $10,241,000 after purchasing an additional 8,343 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Artivion in the 4th quarter worth approximately $275,000. Natixis Advisors LLC acquired a new stake in shares of Artivion in the 4th quarter worth approximately $310,000. Intech Investment Management LLC boosted its holdings in shares of Artivion by 77.5% in the fourth quarter. Intech Investment Management LLC now owns 18,695 shares of the company's stock valued at $534,000 after acquiring an additional 8,165 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Artivion by 5.0% during the fourth quarter. American Century Companies Inc. now owns 57,771 shares of the company's stock valued at $1,652,000 after acquiring an additional 2,764 shares during the period. Institutional investors own 86.37% of the company's stock.

Artivion Stock Down 0.5%

Shares of NYSE:AORT traded down $0.16 during trading hours on Monday, reaching $31.09. The stock had a trading volume of 216,006 shares, compared to its average volume of 320,589. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -62.17 and a beta of 1.62. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.95 and a current ratio of 5.53. The firm's 50 day moving average is $30.03 and its 200-day moving average is $27.85. Artivion has a 1 year low of $21.97 and a 1 year high of $32.94.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. The firm had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Research analysts predict that Artivion will post 0.37 earnings per share for the current fiscal year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.